MyExo and Women’s Intimate Health: What the First Exomine Study Shows
Female sexual dysfunction, including reduced sensation, lower arousal and difficulty reaching orgasm, affects quality of life and relationships, yet treatment options remain limited. Regenerative gynaecology has used platelet-rich plasma (PRP) in the genital area for years. Platelet-derived exosomes are the next step: nanoscale messengers released by the patient’s own platelets that carry growth factors and signalling molecules to surrounding tissue.
MyExo delivers 12 trillion exosomes in a 10 mL final volume, with an average exosome size of 120 nm (±15).
The first published study of Exomine in intimate health
In 2025, the Aesthetic Surgery Journal published a study by Dr Savas Ozgur Aglamis, a gynaecologist in Istanbul, in which the autologous exosome-rich plasma was prepared with the Exomine kit, the T-LAB platform on which MyExo is based. The author describes it as the first application of PRP-derived exosomes to the genital area.
Product characterisation
- Mean particle size: 111.6 nm (nanoparticle tracking analysis)
- Exosome markers CD9 and CD81 present; platelet markers CD41 and CD61 present
- Leukocyte marker CD45 negative, confirming platelet origin
- Viability (7-AAD): 98.9%
Study design
- 60 women aged 29–48 with sexual dysfunction diagnosed by DSM-5 criteria, in four groups of 15
- Each group received 2 cc at one site: the clitoral glans, the anterior vaginal wall (G-spot area), the periurethral area, or the junction of the frenulum, prepuce and labium minus (a newly defined point)
- Three sessions, four weeks apart, under topical anaesthetic cream
- Sexual function measured with the Female Sexual Function Index (FSFI) before treatment and 6 and 12 months after the last session
Results
- FSFI scores rose significantly in every group (P < .001): from 21.95 to 27.15, 15.62 to 23.19, 15.26 to 22.13 and 21.96 to 28.78
- All sub-domains improved: desire, arousal, lubrication, orgasm and satisfaction, while pain scores fell
- No serious adverse effects; only minor itching, redness and mild pain
Why it may work
Exosomes stimulate fibroblasts, collagen and elastin production and remodelling of the extracellular matrix, and promote new blood-vessel formation. In intimate tissue, better tissue quality and blood flow are thought to support sensation and lubrication. Because the material comes from the patient’s own blood, the risk of allergy or rejection is very low.
What to keep in mind
This was a single-centre retrospective study with no placebo group, and the author calls for larger randomised trials to confirm the findings and their long-term durability. Intimate regenerative procedures should only be performed by a qualified gynaecologist after a full assessment, and in line with local regulations.
Reference: Aglamis SO. Platelet-Derived Exosome Vulvar Injections for Sexual Dysfunction: A Retrospective Review. Aesthet Surg J. 2025;45(9):922–927. doi:10.1093/asj/sjaf104
For healthcare professionals. This article summarises published research and is general in nature; it is not medical advice. Treatment decisions should be made by a qualified physician. MyExo by Elixir is distributed by Bionics Medical in the UAE and Saudi Arabia.